RxDoctor Payments Data

Marshall Lauer, MD

Internal Medicine · Collingswood, NJNPI 1306800859

Payments from drug & device makers

$13,859in general payments, 2019–2025

Across 626 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Biodelivery Sciences International, Inc.$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$906
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$675
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$1,75013%
  • Food & beverage$12,00287%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,859 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$112,518
Medicare patients
126
Services billed
1,326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl41$58,216
KerendiaFinerenone67$51,292
OzempicSemaglutide34$50,935
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,970
FarxigaDapagliflozin Propanediol44$42,202
BelbucaBuprenorphine Hcl45$33,008
EliquisApixaban21$25,139
Nucynta ErTapentadol Hcl12$18,622
JardianceEmpagliflozin11$18,274
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl69$14,631
LinzessLinaclotide21$10,533
Oxycodone Hcl332$9,942
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$7,908
FetzimaLevomilnacipran Hcl11$6,410
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen208$5,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er$483$51,63057 claims
BayerKerendia$2,007$51,29267 claims
Novo NordiskOzempic$906$50,93534 claims
AstraZenecaFarxiga$1,895$42,20244 claims
PfizerEliquis$304$25,13921 claims
Boehringer IngelheimJardiance$149$18,27411 claims
AbbVieLinzess, Fetzima$1,881$16,94232 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$87$4,71813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Collingswood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →